Qinglin Che is currently a senior scientist in the CMC group at Synta Pharmaceuticals Inc. based in Lexington, MA, where his main responsibilities include both chemical process research and development for preclinical programs, and API manufacturing process troubleshooting, validation and Optimization to support clinical development and commercialization. Qinglin is also involved in the regulatory document preparations, technical transfer, and outsourcing management. Prior to taking current position in 2011, Qinglin held six years’ experience in small molecule drug discovery, focusing on the identification and lead optimization of various small molecule compounds targeting inflammation and oncology. Qinglin received his Ph.D. with Prof Barry Snider in organic chemistry from Brandeis University in 2005, where he completed the total syntheses of natural products cladobotryal and symbioimine. Qinglin was a Procter & Gamble Fellowship recipient and a summer research associate at P&G Pharmaceuticals in 2002. He received his Bachelor and master degrees in Chemical Engineering from Dalian University of Technology. Qinglin has co-authored over 20 publications including 3 issued patents. Qinglin serves as VP of Chinese American BioMedical Association and Chief Editor for its membership publication, CABA Connect.